Ursodeoxycholic acid nano suspension and preparation method thereof

A technology of ursodeoxycholic acid and nano-suspension, which is applied in the direction of pharmaceutical formulas, medical preparations containing non-active ingredients, medical preparations containing active ingredients, etc., can solve problems such as being left behind, increase absorption opportunities, improve Wettability, the effect of solving physical stability problems
CN101606906AInactive Publication Date: 2009-12-23302 MILITARY HOSPITAL OF CHINA
0 Cites 11 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
302 MILITARY HOSPITAL OF CHINA
Publication Date
2009-12-23
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses an ursodeoxycholic acid nano suspension and a preparation method thereof, relates to the field of pharmaceutical nano formulation, and particularly relates to an ursodeoxycholic acid nano suspension for curing cholestatic cirrhosis and dry powder thereof. The ursodeoxycholic acid nano suspension is characterized by adopting SDS and PVP K30 as surfactants and combining the SDS and the PVP K30 in a weight ratio of 1:1-1:3; and the ursodeoxycholic acid nano suspension has stable quality, with particle size of about 200-800nm. The invention also discloses a preparation method of the suspension.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to the field of pharmaceutical preparations, in particular to a nano-suspension of ursodeoxycholic acid and its dry powder. The invention also discloses a preparation method thereof. Background technique

[0002] Ursodeoxycholic acid (chemical name: 3a, 7β-dihydroxy-5β-cholestane-24-acid, molecular formula: C 24 h 40 o 4 ) is currently the only drug of choice approved by the FDA for various cholestatic liver diseases such as primary cholestatic cirrhosis and primary sclerosing cholangitis. There are many domestic manufacturers, but the clinical efficacy is not obvious. The bottleneck problem restricting its curative effect is mainly that ursodeoxycholic acid is a poorly soluble drug, and its dissolution is limited. If there is no dissolution, there will be no pharmacokinetic behavior such as absorption, and of course it will be ineffective or weak.

[0003] At present, the commonly used pharmaceutical methods to improve the b...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More